2021 Programme


07:30 Registration opens

10:00 – 10:05 Welcome and Introduction, J. Barker (London, UK), C. Griffiths (Manchester, UK)

Scientific Session 1

10:05 – 10:15      FC – 1

IL-17C increases the expression of psoriasis-associated genes by an IκBζ-dependent mechanism in human keratinocytes
Pernille Ommen, Lars Iversen, Claus Johansen

10:15 – 10:25      FC – 2

Differential chromatin accessibility and gene expression in CD4 vs. CD8, resting vs. activated, and skin-homing vs. non-skin- homing T-cells
Zhaolin Zhang, Yi Zhao, Lam Tsoi, Rajan Nair, Philip Stuart, Xiaoquan Wen, James Elder

10:25 – 10:35      FC – 3

International GWAS meta-analysis identifies 49 new psoriasis-associated genetic loci
Nick Dand, for the International Psoriasis GWAS Consortium

10:35 – 11:05 Invited Speaker: Driving discovery in psoriasis with human genetics M. Simpson (London, UK)

11:05 – 11:45 Coffee break – Please visit the virtual exhibition booths and eposters

11:45 – 11:55      FC – 4

Spesolimab alters the molecular profile of lesional skin in patients with generalized pustular psoriasis with a clinical response
Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, Akimichi Morita, Mark Lebwohl, Jonathan N Barker, Siew Eng Choon, David Burden, German Leparc, Denis Delic, Sebastian Bossert, Christian Thoma, James G Krueger

11:55 – 12:05     FC – 5

Transcriptomes of MPO-deficient patients with generalized pustular psoriasis reveals expansion of CD4+ cytotoxic T cells and an involvement of the complement system
Ulrike Hüffmeier

12:05 – 12:15     FC – 6

Single-cell RNA-sequencing reveals systemic T cell abnormalities in palmar plantar pustulosis
Daniel McCluskey, Satveer Mahil, The APRICOT and PLUM study team, Sudha Visvanathan, Patrick Baum, Jonathan Barker, Catherine Smith, Francesca Capon

12:15 – 12:45 Invited Speaker: The Role of IL-36 in Psoriasis J. Gudjonsson (Ann Arbor, USA)

12:45 – 13:45 Lunch

Scientific Session 2

13:45 – 13:55     FC – 7

Inhibition of DNA methylation by decitabine exacerbated IMQ-induced psoriasis-like dermatitis
Chunyuan Guo, Yangfeng Ding, Yuling Shi

13:55 – 14:25 Invited Speaker: Animal models for Psoriasis N.Ward (Cleveland, USA)

14:25 – 14:35     FC – 8

CD8+ T-cell cross-reactivity between wheat antigen and the psoriasis autoantigen ADAMTSL5 may trigger the HLA-C*06:02-mediated autoimmune response against melanocytes in psoriasis
Tatsushi Ishimoto, Yukiyasu Arakawa, Seçil Vural, Sigrid Vollmer, Yuri Poluektov, Marc C Delcommenne, Akiko Arakawa, Jörg C Prinz

14:35 – 14:45     FC – 9

Characterization of the gut microbiota in patients with psoriasis
Tanja Todberg, Alexander Egeberg, Claus Zachariae, Nikolaj Sørensen, Oluf Borbye Pedersen, Lone Skov

14:45 – 15:30 Keynote lecture: Host microbe interactions in the intestine: New therapeutic strategies for the treatment of immune-mediated diseases F. Powrie (Oxford, UK)

15:30 – 16:15 Tea break

16:15 – 16:45 Almirall Sponsored Lecture: Feeling POSITIVE about the brain and skin A. Bewley (London, UK), C. Bundy (Cardiff, UK)

16:50 – 17:20 UCB Pharma Sponsored Lecture: A family affair: IL-17 cytokines as drivers of inflammation in psoriatic disease S. Shaw (Slough, UK)

17:30 – 19:30 Welcome Reception, QEII Centre


Scientific Session 3

08:00 – 08:30 AbbVie Sponsored Lecture: Differences in pathway Inhibition on modulation of the molecular profile in psoriatic disease L. Savage (Leeds, UK)

08:35 – 09:05 Janssen Sponsored Lecture: Joining the conversation on our evolving understanding of psoriasis and PsA management strategies: IL-23 pathway inhibition K. Shams (Leeds, UK), B. Kirkham (London, UK)

09:05 – 09:15 FC – 10

Barriers to Healthcare Access for Patients with Psoriasis
Yasmin Derayat, Jeffrey Toy, Allison Gregory, Wingfield Rehmus

09:15 – 09:25 FC – 11

Human papilloma virus infection as an antigenic stimulus in psoriasis.
Oonagh Molloy, Michael Carr, Gabo Gonzalez, Janet Mc Cormack, Aurelie Fabre, Cillian De Gascun, Brian Kirby

09:25 – 09:35 FC – 12

Are we underestimating dermatology life quality index values in the era of Covid-19?
Niamh Kearney, Ali Alsharqi, Brian Kirby

09:35 – 10:05 Invited Speaker: Addressing global unequal access to care W. Rehmus (Vancouver, Canada)

10:05 – 10:35 Coffee break

10:35 – 10:45 FC – 13

Psoriasis and the risk of cancer development: pooled population-based cohort studies from Denmark, England, Israel and Taiwan.
Alex M Trafford, Yochai Schonmann, Teng-Chou Chen, Alexander Egeberg, Rosa Parisi, Evangelos Kontopantelis, Ting-Chun Wang, Martin K Rutter, Li-Chia Chen, Tjeerd Van Staa, Meng-Sui Lee, Khalaf Kridin, Arnon D Cohen, Kin-Wei Arnold Chan, Christopher EM Griffiths, Darren M Ashcroft

10:45 – 11:15 Invited Speaker: The Epidemiology of Psoriasis and the Global Psoriasis Atlas D. Ashcroft (Manchester, UK)

11:15 – 11:25 FC – 14

HLA-C*06:02 allele is associated with higher drug survival in psoriasis patients on ustekinumab: an analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). On behalf of BADBIR and BSTOP study groups
Oras Alabas, Kayleigh Mason, Zenas Yiu, Richard Warren, Nick Dand, Jonathan Barker, Catherine Smith, Christopher Griffiths

11:25 – 11:35 FC – 15

Development of anti-drug antibodies to adalimumab is associated with amino acid variation within the HLADRB1 peptide-binding groove
Teresa Tsakok, Jake Saklatvala, Theo Rispens, Floris C. Loeff, Annick de Vries, Michael H. Allen, Ines A. Barbosa, David Baudry, Tejus Dasandi, Michael Duckworth, Freya Meynell, Alice Russell, Anna Chapman, Sandy McBride, Kevin McKenna, Gayathri Perera, Helen Ramsay, Raakhee Ramesh, Kathleen Sands, Alexa Shipman, the BSTOP Study Group, A David Burden, Christopher E. M. Griffiths, Nick J. Reynolds, Richard B. Warren, Satveer Mahil, Jonathan Barker, Nick Dand, Catherine Smith, Michael Simpson

11:35 – 12:20 Keynote lecture: Improving human health through science F. Watt (London, UK)

12:20 – 13:25 Lunch

Scientific Session 4

13:25 – 13:35 FC – 16

The impact of the COVID-19 pandemic on people with psoriasis: an update from the PsoProtect and PsoProtectMe global registries
Satveer Mahil, Nick Dand, Katie Bechman, Emma Cook, Teresa Tsakok, Zenas Yiu, Sinead Langan, Helen McAteer, James Galloway, Kayleigh Mason, Richard Warren, Francesca Capon, Paola DiMeglio, Freya Meynell, Bola Coker, Alexandra Vincent, Jade Kelly, Dominic Urmston, Amber Vesty, Camille Lancelot, Herve Bachelez, C Contreras, Claudia De La Cruz, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Sam Norton, Luis Puig, Phyllis Spuls, Tiago Torres, Hosea Waweru, Lucy Moorhead, Mark Yates, John Weinman, Matt Brown, Christopher Griffiths, Jonathan Barker, Catherine Smith

13:35 – 13:45 FC – 17

Antibody responses to SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease
Ali Al-Janabi, Zoe Littlewood, Christopher Griffiths, Hamish Hunter, Hector Chinoy, Chris Moriarty, Zenas Yiu, Jimmy Limdi, Richard Warren

13:45 – 13:55 FC – 18

The impact of methotrexate and targeted immunosuppression on humoral and cellular immunogenicity of the COVID-19 vaccine BNT162b2 in people with psoriasis: a prospective longitudinal cohort study
Satveer Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Freya Meynell, Matt Brown, Andrew Cope, Tejus Dasandi, Carl Graham, Thomas Lechmere, Michael Malim, Emily Pollock, Jeffery Seow, Kamila Sychowska, Sam Norton, Jonathan Barker, James Galloway, Katie Doores, Tim Tree, Catherine Smith

13:55 – 14:05 FC – 19

HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis; efficacy, safety and biomarker results in an open label, proof-of-concept study
Anne Bregnhøj, Katrine K H Thuesen, Thomas Emmanuel, Thomas Litman, Christina L Grek, Gautam S Ghatnekar, Claus Johansen, Lars Iversen

14:05 – 14:15 FC – 20

Drug survival of guselkumab, ixekizumab, secukinumab, ustekinumab and adalimumab for psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Zenas Yiu, on behalf of the BADBIR study group

14:15 – 14:45 Invited Speaker: Innovation in clinical trials to transform practice M. Parmar (London, UK)

14:45 – 15:30 Tea break

Scientific Session 5

15:30 – 15:40 FC – 21

Differences in clinical features and comorbid burden between HLA-C*06:02 carrier groups in more than 9,000 people with psoriasis
Kontantinos Douroudis, Ravi Ramessur, Satveer Mahil, Ines Barbosa, Richard Warren, Christopher Griffiths, Michael Simpson, Jonathan Barker, Nick Dand, Catherine Smith

15:40 – 15:50 FC – 22

Genetic validation of UK Biobank psoriasis diagnoses supports the utility of self-reported data for large scale genetic and epidemiological studies
Jake Saklatvala, Ken Hanscombe, Satveer Mahil, Jonathan Barker, Michael Simpson, Catherine Smith, Nick Dand

15:50 – 16:35 Keynote Lecture: Polygenic risk scores and their potential for clinical impact P. Donnelly (Oxford, UK)

16:35 – 17:05 Lilly Sponsored Lecture: Consistency Counts: From Clinical Trials to Real-World Evidence B. Kirby (Dublin, Ireland)

17:10 – 17:40 Boehringer Ingelheim Sponsored Lecture: Redefining generalized pustular psoriasis: Insights from pathogenesis and clinical burden D Burden (Glasgow, UK) A Van Voorhees (Virginia, USA)

19:30 – 23:00 Congress Dinner


Scientific Session 6

08:40 – 09:10 Novartis Sponsored Lecture: Reflections from latest translational research studies in psoriasis F. Kolbinger (Basel, Switzerland)

09:15 – 09:45 BMS Sponsored Lecture: Allosteric kinase inhibition via a pseudokinase domain R. Moslin (New Jersey, USA)

09:45 – 09:55 FC – 23

Systemic immune-inflammation index as a predictor of systemic inflammatory burden and cardiovascular co-morbidities in psoriasis
Niamh Kearney, Ali Alsharqi, Brian Kirby

09:55 – 10:05 FC – 24

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin3 Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Qingxuan Song, Michelle Miron

10:05 – 10:15 FC – 25

IL-4/IL-13 blockade is associated with psoriatic disease- evidence from the clinic and in vitro
Charlie Bridgewood, Nicola Luigi Bragazzi, Giovanni Damiani, Miriam Wittmann, Dennis McGonagle

10:15 – 10:45 Invited Speaker: Paradoxical reactions to biologics: mechanisms, features and management C. Conrad (Lausanne, Switzerland)

10:45 – 11:15 Coffee Break

11:15 – 11:25 FC – 26

Relative frequency of monocyte subsets at baseline in psoriasis is associated with clinical outcome to secukinumab therapy
Jonathan A Hardman-Smart, Rosa Andres Ejarque, Shane Solanky, Isabella Tosi, Katarzyna Grys, Esme Nichols, Federica Villanova, Michael R Barnes, Jonathan Barker, Christopher EM Griffiths, Nick J Reynolds, Catherine H Smith, Richard B Warren, Paola Di Meglio, On behalf of the PSORT consortium

11:25 – 11:35 FC – 27

IFN-γ amplifies keratinocyte inflammatory responses in psoriasis through suppression of miR-149
Ankit Srivastava, Longlong Luo, Nupur Khera, Warangkana Lohcharoenkal, Florian Meisgen, Lorenzo Pasquali, Andor Pivarcsi, Enikö Sonkoly

11:35 – 12:05 Invited Speaker: Early intervention: rationale, strategies and measuring outcome L. Iversen (Aarhus, Denmark)

12:05 – 12:15 FC – 28

Pathway Inhibition by Risankizumab Differentially Modulates the Molecular Profile in Psoriatic Skin Compared with Ustekinumab
Lourdes Pablo, Nick J Reynolds, Johann Gudjonsson, Julie Parmentier, Feng Hong, Kathleeen Smith, Sandra Garcet, James Krueger

12:15 – 12:25 FC – 29

The pathogenic psoriatic autoimmune response against melanocytes is ERAP1-dependent
Jörg C. Prinz, Sigrid Vollmer, Emma Reeves, Edd James, Akiko Arakawa

12:25 – 12:35 FC – 30

Serum Drug Levels and Anti-Drug Antibodies in the Context of Dose Tapering by Interval Prolongation of Adalimumab, Etanercept and Ustekinumab in Psoriasis Patients: Results of the Randomized Controlled CONDOR trial.
Selma Atalay, Sophie Berends, Hans Groenewoud, Ron Mathot, Marcellus Njoo, Johannes Mommers, Paul Ossenkoppele, Marjolein Koetsier, Maartje Berends, Annick de Vries, Peter van de Kerkhof, Alfons den Broeder, Elke de Jong, Juul van den Reek

12:35 – 13:20 Keynote lecture: Progress in Unravelling the Complexities of Psoriasis Immunology J. Krueger (New York, USA)

13:20 Presentation of poster prizes and close of Congress: J. Barker (London, UK), C. Griffiths (Manchester, UK)

Official Language

All congress sessions will be in English.